AUC and Cmax [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2015-07-02 19:37 (4016 d 09:58 ago) – Posting: # 15024
Views: 10,275

Dear Dr. S. Gunasakaran,

❝ It's surprising to see that the HVDP classification is based on the within subject coefficient of variation of AUC alone and not based on AUC and/or Cmax.


Last year HC considered FDA’s approach (see here). On many previous occasions HC stated that they don’t see any need for changing the requirement for Cmax since for more than two decades only the T/R-ratio had to be contained within 80–125%, which – in HC’s opinion – was never an obstacle con­sidering the necessary sample sizes. László Endrényi and László Tóthfalusi showed many times that for high CVs (say ≥50%) only the restriction on the point estimate leads the BE-decision (irrespective of the scaling method).

Therefore, I understand the logic behind:

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
295 visitors (0 registered, 295 guests [including 25 identified bots]).
Forum time: 05:35 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5